<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03659916</url>
  </required_header>
  <id_info>
    <org_study_id>A4250-008</org_study_id>
    <nct_id>NCT03659916</nct_id>
  </id_info>
  <brief_title>Long Term Safety &amp; Efficacy Study Evaluating The Effect of A4250 in Children With PFIC</brief_title>
  <official_title>An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of A4250 in Children With Progressive Familial Intrahepatic Cholestasis Types 1 and 2 (PEDFIC 2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Albireo</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Albireo</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open Label Extension Study to evaluate long term safety and persistence of effect of A4250 in
      children with PFIC.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 28, 2018</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Pruritus</measure>
    <time_frame>From baseline over 72 weeks</time_frame>
    <description>Change in pruritus as indexed by caregiver-reported (Albireo ObsRO instrument) observed scratching</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in serum bile acids</measure>
    <time_frame>From baseline up to week 72</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>From baseline to weeks 24, 48, and 72</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients undergoing biliary diversion surgery</measure>
    <time_frame>From baseline to weeks 24, 48, and 72</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients undergoing liver transplantation</measure>
    <time_frame>From baseline to weeks 24, 48, and 72</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in growth</measure>
    <time_frame>From baseline to weeks 24, 48, and 72</time_frame>
    <description>The linear growth deficit compared to the standard growth curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in AST to platelet ratio idex (APRI) score</measure>
    <time_frame>From baseline to week 72</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fib-4 score</measure>
    <time_frame>From baseline to week 72</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in pediatric end-stage liver disease (PELD)/model for end-stage liver disease (MELD) score</measure>
    <time_frame>From baseline to week 72</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in use of antipruritic medication</measure>
    <time_frame>From baseline to weeks 24, 48, and 72</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Progressive Familial Intrahepatic Cholestasis</condition>
  <arm_group>
    <arm_group_label>A4250</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Capsules for oral administration (120 ug/kg) once daily for 72 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>A4250 (odevixibat)</intervention_name>
    <description>A4250 is a small molecule and selective inhibitor of IBAT</description>
    <arm_group_label>A4250</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria Cohort 1:

          1. Completion of the 24-week Treatment Period of Study A4250-005 or withdrawn from Study
             A4250-005 due to patient/caregiver judgment of intolerable symptoms after completing
             at least 12 weeks of treatment

          2. Signed informed consent and assent as appropriate

          3. Patients expected to have a consistent caregiver for the duration of the study

          4. Caregivers (and age appropriate patients) must be willing and able to use an eDiary
             device as required by the study

        Inclusion Criteria Cohort 2:

          1. A male or female patient with a clinical diagnosis of PFIC and with a body weight ≥5
             kg

          2. Patient must have clinical genetic confirmation of PFIC

          3. Patient must have elevated serum bile acid levels

          4. Patient must have history of significant pruritus

          5. Age appropriate patients are expected to have a consistent caregiver for the duration
             of the study

          6. Caregivers and age-appropriate patients (≥8 years of age) must be willing and able to
             use an eDiary device as required by the study

        Exclusion Criteria Cohort 1:

          1. Decompensated liver disease: coagulopathy, history, or presence of clinically
             significant ascites, variceal hemorrhage, and/or encephalopathy

          2. Sexually active males and females who are not using a reliable contraceptive method
             with ≤1% failure rate (such as hormonal contraception, intra-uterine device, or
             complete abstinence) throughout the duration of the study and 90 days thereafter

          3. Patients not compliant with treatment in study A4250-005

          4. Any other conditions or abnormalities which, in the opinion of the investigator or
             Medical Monitor, may compromise the safety of the patient, or interfere with the
             patient participating in or completing the study

        Exclusion Criteria Cohort 2:

          1. Known pathologic variations of the ABCB11 gene that have been demonstrated to result
             in complete absence of the BSEP protein

          2. Patient with past medical history or ongoing presence of other types of liver disease
             including, but not limited to, the following:

               1. Biliary atresia of any kind

               2. Benign recurrent intrahepatic cholestasis, indicated by any history of normal
                  serum bile acids

               3. Suspected or proven liver cancer or metastasis to the liver on imaging studies

               4. Histopathology on liver biopsy is suggestive of alternate non-PFIC related
                  etiology of cholestasis

          3. Patient with past medical history or ongoing chronic (i.e., &gt;3 months) diarrhea

          4. Any patient with suspected or confirmed cancers except for basal cell carcinoma

          5. Patient has had a liver transplant, or a liver transplant is planned within 6 months
             of the Screening/Inclusion Visit

          6. Decompensated liver disease

          7. Patient suffers from uncontrolled, recalcitrant pruritic condition other than PFIC

          8. Patient previously treated with an IBAT inhibitor and whose pruritus did not respond
             to treatment

          9. Sexually active males and females who are not using a reliable contraceptive method
             with ≤1% failure rate (such as hormonal contraception, intra-uterine device, or
             complete abstinence) throughout the duration of the study and 90 days thereafter
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Albireo Pharma</last_name>
    <phone>(857) 378-2035</phone>
    <email>medinfo@albireopharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Emory University School of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30329</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins School of Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center - Presbyterian Hospital Building</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine - Texas Children's Liver Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Royal Children's Hospital</name>
      <address>
        <city>Melbourne</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint-Luc</name>
      <address>
        <city>Woluwe-Saint-Lambert</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University and Pediatric Hospital of Lyon</name>
      <address>
        <city>Bron</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universite Paris SUD - Hpitaux Universitaires Paris-Sud - Hopital Bicetre</name>
      <address>
        <city>Le Kremlin-Bicêtre</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital De La Timone</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Necker-Enfants Maladies</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kinderklinik Tubingen, Universitatsklinikum Tubingen</name>
      <address>
        <city>Tübingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Univesitatsklinikum Tubingen Klinik fur Kinder und Jugendmedizin</name>
      <address>
        <city>Tübingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shaare-Zedek Mc</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Schneider Children's Medical Center Of Israel</name>
      <address>
        <city>Petach-Tikva</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Papa Giovanni XXIII</name>
      <address>
        <city>Bergamo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Of Padova</name>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ospedale Regina Margherita</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitair Medisch Centrum (UMC) Utrecht</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Instytut Pomnik - Centrum Zarowia Dziecka</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Astrid Lindgren Children's Hospital, Karolinska University Hospital</name>
      <address>
        <city>Solna</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gazi University</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hacettepe University Faculty of Medicine</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Akdeniz University</name>
      <address>
        <city>Antalya</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Istanbul University Medical Faculty</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Inonu University Medical Faculty</name>
      <address>
        <city>Malatya</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Birmingham Women's and Children's NHS Foundation Trust</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Leeds General Infirmary</name>
      <address>
        <city>Leeds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institute of Liver Studies - Kings College Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>August 24, 2018</study_first_submitted>
  <study_first_submitted_qc>September 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 6, 2018</study_first_posted>
  <last_update_submitted>January 16, 2020</last_update_submitted>
  <last_update_submitted_qc>January 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pediatric</keyword>
  <keyword>Cholestasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholestasis</mesh_term>
    <mesh_term>Cholestasis, Intrahepatic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

